Twist Bioscience Corporation (TWST) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Twist Bioscience Corporation (TWST) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How TWST Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -3.4% | -$77.7M | -$75.6M | -27.6% |
| FY 2024 | $4.00B | 0% | -5.5% | -$208.7M | -$69.2M | -45% |
| FY 2023 | $4.00B | 0% | -5.4% | -$204.6M | -$142.5M | -4.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TWST)
- ✓Live walkthrough of TWST's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
TWST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TWST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TWST. Explore sector supply chains on /butterfly.
TWST Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Twist Bioscience Corporation (TWST)?
In FY 2025 (10-K), TWST converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).